** Shares of Summit Therapeutics SMMT.O settle 36% lower to $23.47 at close, last up 3.81% to $24.36 in after-market trade
** Co says in the submission for cancer drug ivonescimab in China by partner Akeso 9926.HK, the regulators asked for an interim analysis of overall survival
** The drug was approved in China based on a trial that studied it against Merck's MRK.N Keytruda in patients with a type of lung cancer
** The analysis showed a potential 22% reduced risk of death, with a hazard ratio of 0.777, which is not statistically significant, two analysts said
** The simple fact that this still early cut is not statistically significant is triggering a massive sell-off - Evercore ISI
** Summit said the interim analysis was conducted at 39% data maturity
** Brokerage Truist expects overall survival benefit will reach statistical significance by the final analysis, if not potentially earlier
** SMMT shares peaked in September 2024 after results from a study in China showed some lung cancer patients had better survival rates than Keytruda
** Stock up 31.5% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.